UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest

Not Applicable

Completed

Conditions: Cardiac Arrest

Interventions: Behavioral: Telephone simulation training

First Posted Date: 2013-10-30

Last Posted Date: 2016-11-09

Lead Sponsor: University of Washington

Target Recruit Count: 157

Registration Number: NCT01972087

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Phase 2

Terminated

Conditions: Stage IV Skin Melanoma
Recurrent Melanoma

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2013-10-28

Last Posted Date: 2020-02-13

Lead Sponsor: University of Washington

Target Recruit Count: 23

Registration Number: NCT01970527

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Body-oriented Therapy for Women in SUD Treatment

Not Applicable

Completed

Conditions: Substance Use Disorder

Interventions: Behavioral: Mindful Awareness in Body-oriented Therapy
Behavioral: Womens Health Education

First Posted Date: 2013-10-10

Last Posted Date: 2018-10-12

Lead Sponsor: University of Washington

Target Recruit Count: 217

Registration Number: NCT01960036

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Terminated

Conditions: Triple-Negative Breast Carcinoma
Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Other: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2013-10-08

Last Posted Date: 2021-09-30

Lead Sponsor: University of Washington

Target Recruit Count: 31

Registration Number: NCT01957514

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Northwest Medical Specialties PLLC, Tacoma, Washington, United States

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Phase 1

Completed

Conditions: Stage III Bladder Cancer
Recurrent Bladder Carcinoma
Stage II Bladder Cancer
Stage IV Bladder Cancer

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Drug: Sirolimus
Procedure: Cystectomy

First Posted Date: 2013-09-10

Last Posted Date: 2017-10-20

Lead Sponsor: University of Washington

Target Recruit Count: 21

Registration Number: NCT01938573

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Improving Communication About Serious Illness

Not Applicable

Completed

Conditions: Terminal Care
Communication
Advance Care Planning
Neoplasm Metastasis
Palliative Care
End Stage Liver Disease
Heart Failure
Critical Illness
Chronic Disease
Lung Neoplasms

Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness

First Posted Date: 2013-09-02

Last Posted Date: 2019-03-20

Lead Sponsor: University of Washington

Target Recruit Count: 817

Registration Number: NCT01933789

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Northwest Hospital and Medical Center, Seattle, Washington, United States
🇺🇸
Valley Medical Center, Renton, Washington, United States

and more 3 locations

Harm Reduction With Pharmacotherapy (HaRP)

Phase 2

Completed

Conditions: Alcohol Use Disorder

Interventions: Behavioral: HRC
Other: Placebo
Drug: XR-NTX

First Posted Date: 2013-08-30

Last Posted Date: 2023-05-10

Lead Sponsor: University of Washington

Target Recruit Count: 308

Registration Number: NCT01932801

Locations: 🇺🇸
University of Washington - Harborview Medical Center, Seattle, Washington, United States

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Not Applicable

Terminated

Conditions: Stage IIIA Breast Cancer
Stage II Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer

Interventions: Radiation: fludeoxyglucose F 18
Device: positron emission tomography
Device: dynamic contrast-enhanced magnetic resonance imaging
Other: laboratory biomarker analysis

First Posted Date: 2013-08-29

Last Posted Date: 2023-11-18

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT01931709

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Not Applicable

Completed

Conditions: Stage IIIA Breast Cancer
Stage IB Breast Cancer
Stage IIB Breast Cancer
Estrogen Receptor Positive
Stage IA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
HER2/Neu Negative
Male Breast Carcinoma
Stage IIA Breast Cancer

Interventions: Drug: Fluorothymidine F-18
Procedure: Positron Emission Tomography
Other: Laboratory Biomarker Analysis
Drug: Run-in (short pre-surgery course) of endocrine-targeted therapy

First Posted Date: 2013-08-23

Last Posted Date: 2018-05-15

Lead Sponsor: University of Washington

Target Recruit Count: 28

Registration Number: NCT01928186

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation

Not Applicable

Withdrawn

Conditions: Myopia

Interventions: Other: Spectacles with holographic diffuser and color neutral tint
Other: Spectacles with holographic diffuser and red-blocking tint
Other: Spectacles with color neutral tint
Other: Spectacles with red-blocking tint

First Posted Date: 2013-08-15

Last Posted Date: 2019-08-14

Lead Sponsor: University of Washington

Registration Number: NCT01923675

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy